LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs

LG AI Research and D&D Pharmatech have entered into an agreement to collaborate on the development of next-generation oral peptide drugs. The project focuses on the joint discovery and development of oral peptide therapeutics, utilizing artificial intelligence (AI) technology and expertise in peptide formulation. Peptides are crucial for physiological functions but are typically administered via injection due to their susceptibility to breakdown in the digestive system. The goal is to create tablet-form treatments using AI to improve both the safety and absorption rates of peptide drugs, targeting conditions that currently lack effective therapies. LG AI Research will develop models to design and discover new peptide drug candidates, which will analyze disease-causing substances and identify optimal peptide sequences. D&D Pharmatech will be responsible for the structural design, synthesis, evaluation of selected candidates, formulation for oral administration, and management of preclinical and clinical development. The collaboration will operate through a feedback system, where LG AI Research provides AI-generated candidates that D&D Pharmatech then validates. The agreement was signed at the LG Twin Towers in Seoul, South Korea.